The deal adds to a rapidly-expanding pipeline of NASH candidates at Novo Nordisk, which also includes GLP-1 analogue semaglutide in phase 3 in combination with drugs from Gilead, a long-acting ...

Inventiva’s lanifibranor has been tipped to become a blockbuster in the liver disease non-alcoholic steatohepatitis (NASH) after it became the first drug to hit two regulatory goals in a trial.

Cytotoxic T cells meet complement: granzyme K as a new initiator of inflammation Junyi Zhao Xing Guo Conglei Li Research Highlights 29 May 2025 Cellular & Molecular Immunology Volume: 22, P: 693-695 ...

NAFLD is associated with various metabolic risk factors, such as obesity and diabetes. NAFLD can remain harmless, but in some patients it progresses to non-alcoholic steatohepatitis (NASH).